111 related articles for article (PubMed ID: 8068976)
1. A new radioligand binding assay for cytochrome P450IID1 (CYP2D1) in rat liver microsomes: a tool to predict sparteine/debrisoquine type polymorphism of drugs.
Voss HP; Leurs R; Donnell D; Bast A
J Pharmacol Toxicol Methods; 1994 Jun; 31(3):149-52. PubMed ID: 8068976
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype.
Barham HM; Lennard MS; Tucker GT
Biochem Pharmacol; 1994 Apr; 47(8):1295-307. PubMed ID: 8185638
[TBL] [Abstract][Full Text] [Related]
3. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.
Tyndale RF; Sunahara R; Inaba T; Kalow W; Gonzalez FJ; Niznik HB
Mol Pharmacol; 1991 Jul; 40(1):63-8. PubMed ID: 1857341
[TBL] [Abstract][Full Text] [Related]
4. Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism.
Larrey D; Distlerath LM; Dannan GA; Wilkinson GR; Guengerich FP
Biochemistry; 1984 Jun; 23(12):2787-95. PubMed ID: 6432035
[TBL] [Abstract][Full Text] [Related]
5. The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins.
Niznik HB; Tyndale RF; Sallee FR; Gonzalez FJ; Hardwick JP; Inaba T; Kalow W
Arch Biochem Biophys; 1990 Feb; 276(2):424-32. PubMed ID: 2306106
[TBL] [Abstract][Full Text] [Related]
6. Regional distribution of cytochrome P450 2D1 in the rat central nervous system.
Norris PJ; Hardwick JP; Emson PC
J Comp Neurol; 1996 Mar; 366(2):244-58. PubMed ID: 8698885
[TBL] [Abstract][Full Text] [Related]
7. Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).
Pressacco J; Muller R; Kalow W
Eur J Clin Pharmacol; 1993; 45(3):261-4. PubMed ID: 8276051
[TBL] [Abstract][Full Text] [Related]
8. Mepyramine, a histamine H1 receptor antagonist, inhibits the metabolic activity of rat and human P450 2D forms.
Hiroi T; Ohishi N; Imaoka S; Yabusaki Y; Fukui H; Funae Y
J Pharmacol Exp Ther; 1995 Feb; 272(2):939-44. PubMed ID: 7853212
[TBL] [Abstract][Full Text] [Related]
9. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
Ebner T; Eichelbaum M
Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
[TBL] [Abstract][Full Text] [Related]
10. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
[TBL] [Abstract][Full Text] [Related]
11. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.
Tyndale R; Aoyama T; Broly F; Matsunaga T; Inaba T; Kalow W; Gelboin HV; Meyer UA; Gonzalez FJ
Pharmacogenetics; 1991 Oct; 1(1):26-32. PubMed ID: 1844820
[TBL] [Abstract][Full Text] [Related]
12. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
Ellis SW; Ching MS; Watson PF; Henderson CJ; Simula AP; Lennard MS; Tucker GT; Woods HF
Biochem Pharmacol; 1992 Aug; 44(4):617-20. PubMed ID: 1510710
[TBL] [Abstract][Full Text] [Related]
13. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
Brøsen K; Gram LF
Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the cytochrome P450 isozyme that metabolizes ochratoxin A, using metabolic inducers, inhibitors and antibodies.
Hietanen E; Bartsch H; Béréziat JC; Castegnaro M; Michelon J
IARC Sci Publ; 1991; (115):297-304. PubMed ID: 1820345
[TBL] [Abstract][Full Text] [Related]
16. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
Tyndale RF; Kalow W; Inaba T
Br J Clin Pharmacol; 1991 Jun; 31(6):655-60. PubMed ID: 1867960
[TBL] [Abstract][Full Text] [Related]
17. Thebaine O-demethylation to oripavine: genetic differences between two rat strains.
Mikus G; Somogyi AA; Bochner F; Eichelbaum M
Xenobiotica; 1991 Nov; 21(11):1501-9. PubMed ID: 1763524
[TBL] [Abstract][Full Text] [Related]
18. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
19. Purification and characterization of [3H]mepyramine (histamine H1 antagonist)-binding protein from rat liver: a highly homologous protein with cytochrome P450 2D.
Fukui H; Mizuguchi H; Liu YQ; Wang NP; Hayashi H; Kangawa K; Wakamiya T; Leurs R; Shiba T; Matsuo H
J Biochem; 1995 May; 117(5):993-8. PubMed ID: 8586645
[TBL] [Abstract][Full Text] [Related]
20. Ethylmorphine O-deethylation in isolated rat hepatocytes. Involvement of codeine O-demethylation enzyme systems.
Xu BQ; Aasmundstad TA; Bjørneboe A; Christophersen AS; Mørland J
Biochem Pharmacol; 1995 Feb; 49(4):453-60. PubMed ID: 7872951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
